Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors

Pharmaceutical Research

Volumn 21, Issue 10, 2004, Pages 1862-1866

  Richter, Martin ^a   Gyémánt, Nóra ^b   Molnár, Joséf ^b   Hilgeroth, Andreas ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

absorption; HIV protease inhibitor; intestine; P glycoprotein; perfusion

Indexed keywords

CARBOXYFLUORESCEIN; GLYCOPROTEIN P; H 17; MULTIDRUG RESISTANCE PROTEIN; PINDOLOL; PROTEINASE INHIBITOR; RHODAMINE 123; RITONAVIR; SAQUINAVIR; TALINOLOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CALCULATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; FLOW CYTOMETRY; IC 50; ILEUM; IN SITU HYBRIDIZATION; INTESTINE ABSORPTION; JEJUNUM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ADRENERGIC BETA-ANTAGONISTS; ALGORITHMS; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HIV PROTEASE INHIBITORS; INTESTINAL ABSORPTION; INTESTINES; MALE; MICE; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PERFUSION; PERMEABILITY; PROPANOLAMINES; RATS; RATS, WISTAR; SAQUINAVIR; T-LYMPHOCYTES;

EID: 6344279785     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000045240.81664.be     Document Type: Article

References (18)

1. X. Wie, J. M. Decker, H. Lui, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag.,X. Wu, G. M. Shaw, and J. C. Kappes. Emergence of resistant immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905 (2002).
2. A. Hilgeroth. Dimeric 4-aryl-1,4-dihydropyridines: development of a third class of nonpeptidic HIV-1 protease inhibitors. Min. Rev. Med. Chem. 2:235-245 (2002).
3. R. B. Kim, M. F. Fromm, C. Wandel, B. Leake, A. J. J. Wood, and D. M. Roden. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 Protease inhibitors. J. Clin. Invest. 101:289-294 (1998).
4. L. Profite, V. A. Eagling, and D. J. Back. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 13:1623-1627 (1999).
5. M. T. Huisman, J. W. Smit, H. R. Wiltshire, R. M. W. Hoetelmans, J. H. Beijnen, and A. H. Schinkel. P-Glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol. 59:806-813 (2001).
6. J. Drewe, H. Gutmann, G. Fricker, M. Török, C. Beglinger, and J. Huwyler. HIV Protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem. Pharmacol. 57:1147-1152 (1999).
7. C. Leopold. HIV-protease inhibitors - an overview. Pharm. Uns. Zeit 30:234-239 (2001).
8. M. L. Newell. Mechanism and timing of mother-to-child transmission of HIV-1. AIDS 12:831-837 (1998).
9. G. Moyle and B. Gazzard. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 51:701-712 (1996).
10. J. H. Lin, M. Chiba, I.-W. Chen, J. A. Nishime, F. A. Deluna, M. Yamazaki, and Y. J. Lin. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 A and P-glycoprotein induction. Drug Metab. Dispos. 27:1187-1193 (1999).
11. H. Spahn-Langguth, G. Baktir, A. Radschuweit, A. Okyar, B. Terhaag, P. Ader, A. Hanafy, and P. Langguth. P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 36:16-34 (1998).
12. H. Gutmann, G. Fricker, J. Drewe, M. Toeroek, and D. S. Miller. Interactions of HIV protease inhibitors with ATP-dependant drug export proteins. Mol. Pharmacol. 56:383-389 (1999).
13. A. Hanafy, P. Langguth, and H. Spahn-Langguth. Pretreatment with potent P-glycoprotein ligands my increase intestinal secretion in rats. Eur. J. Pharm. Sci. 12:405-415 (2001).
14. M. M. Cornwell, I. Pastan, and M. M. Gottesmann. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J. Biol. Chem. 262:2166-2170 (1987).
15. A. Hilgeroth, C. Dressler, S. Neuhoff, H. Spahn-Langguth, and P. Langguth. Dimeric 4-aryl-1,4-dihydropyridines as novel HIV-1 protease inhibitors - affinities to intestinal P-glycoprotein. Pharmazie 55:784-785 (2000).
16. R. Yumoto, T. Murakami, Y. Nakamoto, R. Hasegawa, J. Nagai, and M. Takano. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J. Pharmacol. Experim. Therapeut. 289:149-155 (1999).
17. S. D. Flanagan, C. L. Cummins, M. Susanto, X. Liu, L. H. Takahashi, and L. Z. Benet. Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology 64:126-134 (2002).
18. M. P. Draper, R. L. Martell, and S. B. Levy. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br. J. Cancer 75:810-815 (1997).